314 related articles for article (PubMed ID: 20934891)
1. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
Giraldo P; Irún P; Alfonso P; Dalmau J; Fernández-Galán MA; Figueredo A; Hernández-Rivas JM; Julia A; Luño E; Marín-Jimenez F; Martín-Nuñez G; Montserrat JL; de la Serna J; Vidaller A; Villalón L; Pocovi M
Blood Cells Mol Dis; 2011 Jan; 46(1):115-8. PubMed ID: 20934891
[TBL] [Abstract][Full Text] [Related]
2. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.
Stirnemann J; Rose C; Serratrice C; Dalbies F; Lidove O; Masseau A; Pers YM; Baron C; Belmatoug N
Orphanet J Rare Dis; 2015 May; 10():62. PubMed ID: 25968608
[TBL] [Abstract][Full Text] [Related]
3. Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3.
Machaczka M; Kämpe Björkvall C; Wieremiejczyk J; Paucar Arce M; Myhr-Eriksson K; Klimkowska M; Hägglund H; Svenningsson P
Arch Immunol Ther Exp (Warsz); 2015 Feb; 63(1):65-71. PubMed ID: 25205209
[TBL] [Abstract][Full Text] [Related]
4. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
[TBL] [Abstract][Full Text] [Related]
6. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
Weinreb NJ; Camelo JS; Charrow J; McClain MR; Mistry P; Belmatoug N;
Mol Genet Metab; 2021 Feb; 132(2):100-111. PubMed ID: 33485799
[TBL] [Abstract][Full Text] [Related]
7. Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply.
Zimran A; Altarescu G; Elstein D
Blood Cells Mol Dis; 2011 Jan; 46(1):111-4. PubMed ID: 20542712
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement and substrate reduction therapy for Gaucher disease.
Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
[TBL] [Abstract][Full Text] [Related]
9. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
10. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
11. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
[TBL] [Abstract][Full Text] [Related]
12. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Mistry PK; Batista JL; Andersson HC; Balwani M; Burrow TA; Charrow J; Kaplan P; Khan A; Kishnani PS; Kolodny EH; Rosenbloom B; Scott CR; Weinreb N
Am J Hematol; 2017 Sep; 92(9):929-939. PubMed ID: 28569047
[TBL] [Abstract][Full Text] [Related]
13. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
14. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
[TBL] [Abstract][Full Text] [Related]
15. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
[TBL] [Abstract][Full Text] [Related]
16. Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes.
van Dussen L; Cox TM; Hendriks EJ; Morris E; Akkerman EM; Maas M; Groener JE; Aerts JM; Deegan PB; Hollak CE
Haematologica; 2012 Dec; 97(12):1850-4. PubMed ID: 22773601
[TBL] [Abstract][Full Text] [Related]
17. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.
Hollak CE; vom Dahl S; Aerts JM; Belmatoug N; Bembi B; Cohen Y; Collin-Histed T; Deegan P; van Dussen L; Giraldo P; Mengel E; Michelakakis H; Manuel J; Hrebicek M; Parini R; Reinke J; di Rocco M; Pocovi M; Sa Miranda MC; Tylki-Szymanska A; Zimran A; Cox TM
Blood Cells Mol Dis; 2010 Jan; 44(1):41-7. PubMed ID: 19804996
[TBL] [Abstract][Full Text] [Related]
18. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
Heitner R; Arndt S; Levin JB
S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
[TBL] [Abstract][Full Text] [Related]
19. Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia.
Goldblatt J; Fletcher JM; McGill J; Szer J; Wilson M
Blood Cells Mol Dis; 2011 Jan; 46(1):107-10. PubMed ID: 20684886
[TBL] [Abstract][Full Text] [Related]
20. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
Elstein D; Dweck A; Attias D; Hadas-Halpern I; Zevin S; Altarescu G; Aerts JF; van Weely S; Zimran A
Blood; 2007 Oct; 110(7):2296-301. PubMed ID: 17609429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]